Trial reportFrontiers in immunology2021
Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine.
Open access · goldAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
In one paragraph
Trial report in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
4.3field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 67 citations in OpenAlex.
- Trial
- Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.Frontiers in immunology · 2021Trial
- Association between friends' hesitancy and personal COVID-19 vaccine hesitancy among Chinese medical staff.Human vaccines & immunotherapeutics · 2024Article
- Impact of Vaccination on Intra-Host Genetic Diversity of Patients Infected with SARS-CoV-2 Gamma Lineage.Viruses · 2024Article
- Screening for lipid nanoparticles that modulate the immune activity of helper T cells towards enhanced antitumour activity.Nature biomedical engineering · 2024Article
- Article
- Immune responses during COVID-19 breakthrough cases in vaccinated children and adolescents.Frontiers in immunology · 2024Article
- How has research on the effectiveness and safety of COVID-19 vaccination been evaluated: a scope review with emphasis on CoronaVac.Frontiers in public health · 2024Review
- Pathophysiological, immunological, and inflammatory features of long COVID.Frontiers in immunology · 2024Review
- Comparative study of 'the clinical profile of COVID-19-positive patients with and without vaccination profile'.Journal of family medicine and primary care · 2023Article
- Differential Severe Acute Respiratory Syndrome Coronavirus 2-Specific Humoral Response in Inactivated Virus-Vaccinated, Convalescent, and Breakthrough-Infected Subjects.The Journal of infectious diseases · 2023Article
- Single cell characteristics of patients with vaccine-related adverse reactions following inactivated COVID-19 vaccination.Human vaccines & immunotherapeutics · 2023Article
- Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective study.BMC nephrology · 2023Article
- SARS-CoV-2 Breakthrough Infections According to the Immune Response Elicited after mRNA Third Dose Vaccination in COVID-19-Naïve Hospital Personnel.Biomedicines · 2023Article
- Humoral Immune Response to CoronaVac in Turkish Adults.Vaccines · 2023Article
- LAG-3 Contribution to T Cell Downmodulation during Acute Respiratory Viral Infections.Viruses · 2023Review
- Low humoral and cellular immune responses early after breakthrough infection may contribute to severe COVID-19.Frontiers in immunology · 2023Article
- Breakthrough infection evokes the nasopharyngeal innate immune responses established by SARS-CoV-2-inactivated vaccine.Frontiers in immunology · 2023Article
- Upregulated CD8Frontiers in immunology · 2023Article
- Assessment of antibody dynamics and neutralizing activity using serological assay after SARS-CoV-2 infection and vaccination.PloS one · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 4 institutions in 2 countries.
Luisa F DuarteMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Nicolás M S GálvezMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Carolina IturriagaDepartamento de Enfermedades Infecciosas e Inmunología Pediátricas, División de Pediatría, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Felipe Melo-GonzálezMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Jorge A SotoMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Bárbara M SchultzMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Marcela UrzúaDepartamento de Enfermedades Infecciosas e Inmunología Pediátricas, División de Pediatría, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Liliana A GonzálezMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Yaneisi VázquezMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Mariana RíosMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Roslye V Berríos-RojasMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Daniela Rivera-PérezMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Daniela Moreno-TapiaMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Gaspar A PachecoMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Omar P VallejosMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Guillermo Hoppe-ElsholzMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
María S NavarreteDepartamento de Enfermedades Infecciosas del Adulto, División de Medicina, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Álvaro RojasDepartamento de Enfermedades Infecciosas del Adulto, División de Medicina, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Rodrigo A FasceDepartamento de Laboratorio Biomédico, Instituto de Salud Pública de Chile, Santiago, Chile.
Jorge FernándezDepartamento de Laboratorio Biomédico, Instituto de Salud Pública de Chile, Santiago, Chile.
Judith MoraDepartamento de Laboratorio Biomédico, Instituto de Salud Pública de Chile, Santiago, Chile.
Eugenio RamírezDepartamento de Laboratorio Biomédico, Instituto de Salud Pública de Chile, Santiago, Chile.
Gang ZengSinovac Biotech, Beijing, China.
Weining MengSinovac Biotech, Beijing, China.
José V González-AramundizDepartamento de Farmacia, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Santiago, Chile.
Pablo A GonzálezMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Katia AbarcaMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Susan M BuenoMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Alexis M KalergisMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Pontificia Universidad Católica de Chile · CLMillennium Institute on Immunology and Immunotherapy · CLInstituto de Salud Pública de Chile · CLSinovac Biotech · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
Constant efforts to prevent infections by severe acute respiratory syndrome coronavirus 2 (SARS
Indexed as
AdultAgedAntibodies, NeutralizingAntibodies, ViralBreakthrough InfectionsChileComorbidityCOVID-19COVID-19 VaccinesFemaleHumansImmunization ScheduleImmunogenicity, VaccineImmunoglobulin GInterferon-gammaLymphocyte CountAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesIFNG protein, humanImmunoglobulin GInterferon-gammaVaccines, Inactivatedbreakthrough casesCoronaVacCOVID-19phase 3 clinical trialSARS-CoV-2vaccines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.